Neuroimmunopharmacologic Effects of Drugs of Abuse

  • Nicholas R. S. Hall
  • Maureen P. O’Grady
  • Robert A. Menzies
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 288)


The immune system plays a dual role in the context of drug addiction. It is capable of being influenced by neuroactive drugs and at the same time is capable of modulating the pharmacologic action of these substances. In some instances, drugs of abuse may act directly upon cells of the immune system while in others, the actions may be indirect, mediated through changes in neurotransmitter activity. The latter can influence the immune system via the autonomic nervous system and/or neuroendocrine circuits. The opposite is also true. A number of immune system peptides have been found to modulate some of the same neurotransmitter systems which are acted upon by drugs of abuse. Consequently, the relationship between neuroactive pharmacologic compounds and the immune system has to be considered as a bi-directional one.


Withdrawal Symptom Corticotropin Release Factor Adrenergic Stimulation Morphine Withdrawal Electrical Brain Stimulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    D. L. Feiten, S. Y. Feiten, D. L. Bellinger, S. L. Carlson, K. D. Ackerman, K. S. Madden, J. A. Olschowka and S. Livnat, Immunol. Rev. 100:225 (1987).CrossRefGoogle Scholar
  2. 2.
    D. L. Bellinger, K. D. Ackerman, S. Y. Feiten, D. Lorton and D. L. Feiten, in: “Interactions among CNS, Neuroendocrine and Immune Systems,” J. W. Hadden, K. Masek and G. Nistico, eds., Pythagora Press, Rome, Italy (1989).Google Scholar
  3. 3.
    U. Singh, D. S. Millson, P. A. Smith and J. J. T. Owen, Eur, J. Immunol. 9:31 (1979).Google Scholar
  4. 4.
    K. Kasahara, S. Tanaka, T. Ito and Y. Hamashima, Res. Commun. Chem. Pathol. Pharmacol. 16:687 (1977).PubMedGoogle Scholar
  5. 5.
    N. R. Hall, J. E. McClure, S-K. Hu, N. S. Tare, C. M. Seals and A. L. Goldstein, Immunopharm. 5:39 (1982).CrossRefGoogle Scholar
  6. 6.
    K. L. Melmon, H. R. Bourne, Y. Weinstein, G. M. Shearer, S. Bauminger and J. Kram, L Clin Invest. 53:13 (1974).CrossRefGoogle Scholar
  7. 7.
    G. M. Shearer, K. L. Melmon, Y. Weinstein and M. Sela, J. Exp. Med. 136: 1302 (1972).PubMedCrossRefGoogle Scholar
  8. 8.
    U. Singh and J. J. T. Owen, Eur, J. Immunol. 6:59 (1976).CrossRefGoogle Scholar
  9. 9.
    H. O. Besedovsky, A. Del Ray, E. Sorkin, M. Da Prada and H. H. Keller, Cell. Immunol. 48:346 (1979).PubMedCrossRefGoogle Scholar
  10. 10.
    A. del Rey, H. O. Besedovsky, E. Sorkin, M. Da Prada and G. P. Bondiolotti, Am. J. Phvsiol. 242:R30 (1982).Google Scholar
  11. 11.
    G. C. Cotzias and L. C. Tang, Science 197:1094, (1977).PubMedCrossRefGoogle Scholar
  12. 12.
    G. C. Cotzias, S. T. Miller, A. R. Nicholson, Jr., W. H. Mastom and L. C. Tang, Proc. Natl. Acad. Sci. USA 71:2466 (1974).PubMedCrossRefGoogle Scholar
  13. 13.
    G. C. Cotzias, S. T. Miller, L. C. Tang, P. S. Papavasilious and Y. Y. Wang, Science 196:549 (1977).PubMedCrossRefGoogle Scholar
  14. 14.
    P. M. Hoffman, D. S. Robbins, M. T. Nolte, C. J. Gibbs, Jr. and D. C. Gajdusek, J. Supramol. Struct. 8:Suppl. 2 (abstract) (1978).Google Scholar
  15. 15.
    N. R. Hall, J. K. Lewis, R. D. Schimpff, R. T. Smith, A. M. Trescot, H. E. Gray, S. E. Wenzel, W. C. Abraham and S. F. Zornetzer, Soc. Neurosc. Abst. 56:20 (1978).Google Scholar
  16. 16.
    L. V. Devoino and R. Y. Ilyutchenok, Eur, J. Pharmacol. 4:449 (1968).Google Scholar
  17. 17.
    P. E. Segall and P. S. Timiras, Mech. Aging Dev. 5:109 (1976).PubMedCrossRefGoogle Scholar
  18. 18.
    O. F. Eremina and L. V. Devoino, Bull. Exp. Biol. Med. (Engl. Transl.) 75:149 (1973).Google Scholar
  19. 19.
    D. J. O’Brian, F. W. Hughes and J. Newberne, Proc. Soc. Exp. Biol. Med111:490 (1962).Google Scholar
  20. 20.
    J. R. Cooper, F. E. Bloom and R. H. Roth, “The Biochemical Basis of Neuropharmacology,” Oxford University Press, London and New York (1978).Google Scholar
  21. 21.
    G. K. Aghajanian, Nature 276:186 (1978).PubMedCrossRefGoogle Scholar
  22. 22.
    P. S. Distefano and O. M. Brown, Fed. Aa Soc. Exp, Biol. 41:1055 (1982).Google Scholar
  23. 23.
    D. J. Reis, P. Hess and E. C. Armitia, Brain Res. 20:309 (1970).PubMedCrossRefGoogle Scholar
  24. 24.
    G. L. Kovacs, F. Izbeki, Z. Horvath and G. Telgdy, Behav. Brain Res. 14:1 (1984).PubMedCrossRefGoogle Scholar
  25. 25.
    B. Tabakoff, C. L. Melchior and P. L. Hofman, Alcoholism: Clin. Exp. Res6:252 (1982).CrossRefGoogle Scholar
  26. 26.
    S. M. Gabriel, J. W. Simpkins and W. J. Millard, Brain Res. 346:15 (1985).PubMedCrossRefGoogle Scholar
  27. 27.
    A. J. Dunn, Trans. Amer. Soc. Neurochem. 15:203 (1984).Google Scholar
  28. 28.
    N. Schupf, C. A. Williams, T. E. Hugh and J. Cox, J. Neuroimmunol. 5:305 (1983).PubMedCrossRefGoogle Scholar
  29. 29.
    R. Esposito and C. Kornetsky, Science 195:189 (1977).PubMedCrossRefGoogle Scholar
  30. 30.
    J. M. van Ree and A. P. Otte, Neuropharm. 19:429 (1980).CrossRefGoogle Scholar
  31. 31.
    M. A. Bozarth and R. A. Wise, life Sci. 29:551 (1981).CrossRefGoogle Scholar
  32. 32.
    R. A. Wise, Brain Res. 152:215 (1978).PubMedCrossRefGoogle Scholar
  33. 33.
    R. A. Wise, Pharm. Biochem. Behav. 13(Supp. 1):213 (1980).CrossRefGoogle Scholar
  34. 34.
    W. Kiess and N. Hall, in: “Endocrinology (Endokrinologie),” R. D. Hesch, ed., Klinik der Gegenwart Series, Urban & Schwarzenberg, Munich -Baltimore (1989).Google Scholar
  35. 35.
    E. W. Hillhouse, J. Burden and M. T. Jones, Neuroendocrinology 17:1 (1975).PubMedCrossRefGoogle Scholar
  36. 36.
    M. T. Jones, E. W. Hillhouse and J. Burden, J. Endocrinol. 69: 1 (1976).PubMedCrossRefGoogle Scholar
  37. 37.
    J. Wybran, in: “Neural Modulation of Immunity,” R. Guillemin, M. Cohn and T. Melnechuk, eds., Raven Press, New York (1985).Google Scholar
  38. 38.
    C. T. Ambrose, J. Exp, Med 119:1027 (1964).CrossRefGoogle Scholar
  39. 39.
    N. R. Hall and A. L. Goldstein, in: “Immune Modulation Agents and their Mechanisms,” R. L. Fenichel and M. A. Chirigos, eds., Marcel Dekker, New York (1984).Google Scholar
  40. 40.
    H. O. Besedovsky and E. Sorkin, Clin. Exp. Immunol. 27: 1 (1977).PubMedGoogle Scholar
  41. 41.
    H. O. Besedovsky, A. Del Rey, E. Sorkin, M. Da Prada, R. Burri and C. Honnegger, Science 221:564 (1983).PubMedCrossRefGoogle Scholar
  42. 42.
    A. J. Dunn, M. L. Powell, W. V. Moreshead, J. M. Gaskin and N. R. Hall, Brain Behav. Immun. 1:216 (1987).PubMedCrossRefGoogle Scholar
  43. 43.
    A. J. Dunn, Life Sci. 43:429 (1988).PubMedCrossRefGoogle Scholar
  44. 44.
    J. P. Mc-Gillis, N. R. Hall, G. V. Vahouny and A. L. Goldstein, J. Immunol134:3952 (1985).Google Scholar
  45. 45.
    A. Sivas, M. Uysal and H. Oz, Horm. Metab. Res. 14:330 (1982).PubMedCrossRefGoogle Scholar
  46. 46.
    D. C. Dumonde, M. S. Pulley, A. S. Hamblin, A. K. Singh, B. M. Southcott, D. O’Connell, F. J. Paradinas, M. R. G. Robinson, C. C. Rigby, F. den Hollander, A Schuurs, H. Verheul and E. van Vliet, in: “Lymphokines and Thymic Hormones: Their Potential Utilization in Cancer Therapeutics,” A L. Goldstein and M. A. Chirigos, eds., Raven Press, New York (1985).Google Scholar
  47. 47.
    J. P. McGillis, N. R. Hall and A. L. Goldstein, life Sci. 42:2259 (1988).PubMedCrossRefGoogle Scholar
  48. 48.
    J. M. Farah, Jr., N. R. Hall, J. F. Bishop, A. L. Goldstein and T. L. O’Donohue, J. Neurosci. Res. 18:140 (1987).PubMedCrossRefGoogle Scholar
  49. 49.
    A. J. Dunn and N. R. Hall, Brain Behav. Immun. 1:113 (1987).PubMedCrossRefGoogle Scholar
  50. 50.
    N. R. Hall, J. P. McGillis, B. L. Spangelo, E. Palszynski, T. W. Moody and A. L. Goldstein, Dev. Immunol. 17:653 (1982).Google Scholar
  51. 51.
    R. W. Rebar, A. Miyake, T. L. K. Low and A. L. Goldstein, Science 214:669 (1981).PubMedCrossRefGoogle Scholar
  52. 52.
    N. Dafny and N. R. Pellis, Neuropharm. 25:815 (1986).CrossRefGoogle Scholar
  53. 53.
    C. Y. Hung, S. S. Lefkowitz and W. Geber, Proc. Soc. Exp. Biol. Med. 142: 106 (1973)PubMedGoogle Scholar
  54. 54.
    N. Dafny, Neuropharm. 22:647 (1983).CrossRefGoogle Scholar
  55. 55.
    N. Dafny, B. Prieto-Gomez and C. Reyes-Vazquez, J. Neuroimmunol. 9:1 (1985).PubMedCrossRefGoogle Scholar
  56. 56.
    N. Dafny and C. Reyes-Vazquez, Immunopharm. 9:13 (1985).CrossRefGoogle Scholar
  57. 57.
    J. R. Lee, P. M. Dougherty, K. J. Krajewski and N. Dafny, Soc. NeurosciAhst. 254:15 (1987).Google Scholar
  58. 58.
    W. E. Stewart, II “The Interferon System,”, Vienna, Austria (1981).Google Scholar
  59. 59.
    R. Marcovistz, P. M. L. Germano, Y. Riviere, H. Tsiang and A. G. Hovansessian, J. Interferon Res. 7:17 (1987).PubMedCrossRefGoogle Scholar
  60. 60.
    E. Wei, K. F. Tseng, H. Loh, and E. L. Way, Nature 247:398 (1974).PubMedCrossRefGoogle Scholar
  61. 61.
    R. Dantzer, E. Satinoff and K. W. Kelley, Physiol. and Behav. 39:593 (1987).CrossRefGoogle Scholar
  62. 62.
    J. Krueger, C. Dinerello, M. Wolff, L. Chedid and J. Walker, Am. J. Physiol246:R994 (1984).Google Scholar
  63. 63.
    M. S. Ahmed, W. J. Llanos, C. A. Dinarello and C. M. Blatteis, Peptides 6:1149 (1985).PubMedCrossRefGoogle Scholar
  64. 64.
    W. L. Farrar, P. L. Kilian, M. R. Ruff, J. M. Hill and C. B. Pert, in: “Psychological Neuropsychiatric, and Substance Abuse Aspects of AIDS,” T. P. Bridge, A. F. Mirsky and F. K. Goodwin, eds., Raven Press, New York (1988).Google Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Nicholas R. S. Hall
    • 1
  • Maureen P. O’Grady
    • 1
  • Robert A. Menzies
    • 1
  1. 1.Departments of Psychiatry and Behavioral Medicine and Medical Microbiology and ImmunologyUniversity of South Florida College of MedicineTampaUSA

Personalised recommendations